Commercial
Strategy Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Who’s Hired? Formycon Is Latest To Swap CEO
Formycon has become the latest firm to announce a new CEO, after similar moves at Orion and Strides. Meanwhile, Gedeon Richter has made management changes and a new director has joined Coherus.

Alembic Remains Upbeat Despite Rhizen Setback
Disappointment for Alembic-backed Rhizen after partner TG Therapeutics takes Ukoniq off the US market amid wider regulatory scrutiny around the PI3K inhibitor class of drugs. The Indian firm, however, remains upbeat about the US business, which saw significant growth in the fiscal fourth quarter and has 15-plus launches lined up.

IFC And Nippon Chemiphar Ally In Asia, Middle East And Africa
Japan’s Nippon Chemiphar and the International Finance Corporation have announced an alliance that will see the pair collaborate to boost local production of generics in Asia, the Middle East and Africa, as part of efforts to reduce reliance on imports.
Deals Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Endo Buys Six Injectables Amid Shattering Decline In EBITDA Guidance
Endo maintains that it will continue to drive revenue and EBITDA growth via business development opportunities, after the advent of generic competition to its lucrative Vasostrict injectable led the firm to disclose potentially catastrophic Q2 profitability guidance.

IFC And Nippon Chemiphar Ally In Asia, Middle East And Africa
Japan’s Nippon Chemiphar and the International Finance Corporation have announced an alliance that will see the pair collaborate to boost local production of generics in Asia, the Middle East and Africa, as part of efforts to reduce reliance on imports.

Formycon Highlights Greater Focus On Biosimilars As Athos Deal Completes
Formycon has completed its acquisition of Athos’ biosimilar candidates for Stelara and Lucentis, following the announcement of the deal in March.
Manufacturing Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Blow For Prestige As Trastuzumab Biosimilar Rejected By EMA
Prestige Biopharma has received a setback in its attempts to win a European approval for its HD201 trastuzumab biosimilar rival to Herceptin, after the EMA’s CHMP issued a negative opinion on its parallel marketing authorization applications under the Tuznue and Hervelous labels. Prestige has 15 days in which it can ask for a re-examination of the refusals.

IFC And Nippon Chemiphar Ally In Asia, Middle East And Africa
Japan’s Nippon Chemiphar and the International Finance Corporation have announced an alliance that will see the pair collaborate to boost local production of generics in Asia, the Middle East and Africa, as part of efforts to reduce reliance on imports.

Teva: Payers Hold The Cards On Material 2023 Adalimumab Opportunity
Fresh from partner Alvotech resolving patent litigation in the US for its proposed Humira biosimilar, Teva management has detailed the firm’s expectations around the product and the crucial issue of supply.
Sales & Earnings Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
.jpg?rev=95706b9e0a16455aabe94d3ff4f20319&w=350&hash=A5109C72BEEAFFFF2F830D016399CB1B)
Goldman Ends Endo Coverage Following Q2 EBITDA Guide
One of the largest investment banks in the US has cancelled its coverage of Endo after the US-based firm revealed the extent of generic competition to its lucrative Vasostrict brand.

ANI ‘On The Cusp Of A Transformation’ Following Cortrophin Launch
ANI Pharmaceuticals appeared confident about its Cortrophin gel launch and integration of Novitium Pharma as it rounded up its Q1 results, but net losses have dampened the company’s share value.

Alembic Remains Upbeat Despite Rhizen Setback
Disappointment for Alembic-backed Rhizen after partner TG Therapeutics takes Ukoniq off the US market amid wider regulatory scrutiny around the PI3K inhibitor class of drugs. The Indian firm, however, remains upbeat about the US business, which saw significant growth in the fiscal fourth quarter and has 15-plus launches lined up.
People Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Who’s Hired? Formycon Is Latest To Swap CEO
Formycon has become the latest firm to announce a new CEO, after similar moves at Orion and Strides. Meanwhile, Gedeon Richter has made management changes and a new director has joined Coherus.

Burton Takes Lead At AAM’s Biosimilars Council
Craig Burton is stepping up to become executive director of the US Association for Accessible Medicines’ Biosimilars Council, as Christine Simmon has moved on to become president and CEO of the Food and Drug Law Institute. At the same time, Burton has added oversight of strategic alliances to his existing policy role with the AAM.

Revolving Door Of Executive Changes At Perrigo As Firm Revises Its Expectations Up
Perrigo is set to welcome a new chief financial officer and corporate security head as it rounds up a fairly successful first quarter.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.